指南与共识姑息放疗与转移瘤

国际淋巴瘤放疗组织复发难治性霍奇金淋巴瘤放疗指南

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2018-01-09

该指南由国际淋巴瘤放疗组织制定,针对复发或难治性霍奇金淋巴瘤放疗的角色提供指导。文章描述了不同治疗场景,并给出放疗剂量、体积和时机的建议,强调放疗仍是许多患者治疗的重要组成部分,但需有效且审慎使用。

要点

  • 放疗是霍奇金淋巴瘤最有效的单一治疗方式,应理解其在挽救方案中的整合或独立使用。
  • 复发难治患者异质性强,需根据原治疗暴露、复发时间、病灶范围及残留毒性个体化决策。
  • 本指南旨在为复发难治性霍奇金淋巴瘤的放疗剂量、体积和时机提供指导。

核心结论

  • 放疗仍是许多复发或难治性霍奇金淋巴瘤患者治疗的整体组成部分,但必须有效且审慎地使用。

研究设计与样本

  • 国际淋巴瘤放疗组织(ILROG)制定的指南,基于综述不同治疗场景提供放疗剂量、体积和时机的指导。

主要发现

  • 复发或难治性霍奇金淋巴瘤的治疗复杂性源于当前一线治疗方法的差异,导致治疗暴露和挽救治疗潜在毒性的异质性。
  • 患者可能在有限或激进的一线治疗后(伴或不伴放疗)出现复发或难治,时间早晚、病灶范围及原治疗残留 morbidity 各异。
  • 对挽救全身治疗的反应可为部分或完全,巩固性干细胞移植的应用不一,新型生物制剂和免疫治疗拓宽但也复杂化了挽救治疗。

临床怎么用

  • 临床需根据患者原治疗暴露、复发时间、病灶范围、残留毒性及对挽救治疗的反应,个体化决定放疗的整合或独立使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed and refractory Hodgkin lymphoma (HL) challenges clinicians to devise treatment strategies that are effective and safe. This problem is particularly prominent in an era when de-escalation trials are designed to minimize therapeutic toxicities in both early- and advanced-stage disease. Radiation therapy is the single most effective treatment modality for HL, and its integration into salvage regimens, or its independent use in select patients, must be understood to maximize our success in treating these patients. The complexity of treating relapsed or refractory HL derives from the spectrum of primary treatment approaches currently in use that creates heterogeneity in both treatment exposure and the potential toxicities of salvage therapy. Patients can have relapsed or refractory disease after limited or aggressive primary therapy (with or without radiation therapy), at early or delayed time points, with limited or extensive disease volumes, and with varying degrees of residual morbidity from primary therapy. Their response to salvage systemic therapy can be partial or complete, and the use of consolidative stem cell transplantation is variably applied. New biologics and immunotherapeutic approaches have broadened but also complicated salvage treatment approaches. Through all of this, radiation therapy remains an integral component of treatment for many patients, but it must be used effectively and judiciously. The purpose of this review is to describe the different treatment scenarios and provide guidance for radiation dose, volume, and timing in patients with relapsed or refractory HL.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Constine LS, Yahalom J, Ng AK, et al. The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018. PMID: 29722655. doi:10.1016/j.ijrobp.2018.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。